Who is sponsoring NCT06639555?

NCT06639555 is sponsored by Tsvetalina Gerova-Vatsova.

What drugs are being tested in NCT06639555?

Interventions in NCT06639555: PRP( platelet rich plasma), EMD (Enamel Matrix Derivative), Guided Tissue Regeneration (barrier membrane), Guided Tissue Regeneration(barrier membrane and PRP).

What condition does NCT06639555 study?

NCT06639555 studies Vertical Alveolar Bone Loss.

Is NCT06639555 still recruiting?

NCT06639555 is currently completed. Last updated 15 October 2024.

Last reviewed 2024-10-15 · How we verify

NCT06639555

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Initial Clinical and CBCT Outcomes of Enamel Matrix Derivative-Based Regenerative Therapy in Vertical Bone Defects

Completed NA Last updated 15 October 2024

What this trial tests

NA trial testing PRP( platelet rich plasma) in Vertical Alveolar Bone Loss in 48 participants. Completed in 15 August 2023.

Timeline

24 June 2022

Primary endpoint
15 February 2023

15 August 2023

Quick facts

Lead sponsor	Tsvetalina Gerova-Vatsova
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	48
Start date	24 June 2022
Primary completion	15 February 2023
Estimated completion	15 August 2023
Sites	1 location across Bulgaria

Drugs / interventions tested

PRP( platelet rich plasma)
EMD (Enamel Matrix Derivative)
Guided Tissue Regeneration (barrier membrane)
Guided Tissue Regeneration(barrier membrane and PRP)

Conditions studied

Vertical Alveolar Bone Loss — all drugs for Vertical Alveolar Bone Loss →

Sponsor

Tsvetalina Gerova-Vatsova

Who can join

Adults 18 to 65, any sex, with Vertical Alveolar Bone Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study of the effectiveness of the application of regenerative therapy with autogenous, platelet-rich plasma in vertical defects Investigation of the effectiveness of the application of regenerative therapy with enamel matrix derivatives in vertical bone defects Study of the effectiveness of the application of guided tissue regeneration in vertical bone defects with Barrier membrane and Barrier membrane and autogenous platelet-rich plasma

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Beyond Bone Grafts: Exploring the Efficacy of Alternative Regenerative Therapies.
Gerova-Vatsova T. · · 2024 · cited 1× · PMID 39677141 · DOI 10.7759/cureus.73745

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06639555 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tsvetalina Gerova-Vatsova
Last refreshed: 15 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06639555.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing